NCT03568409View on ClinicalTrials.gov

ABO-GLYC in Type 2 Diabetes

NACompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

June 1, 2017

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Type2 Diabetes
Interventions
DEVICE

ABO-GLYC

3 tablets twice a day, before the main meals (lunch and dinner) continuatively for 24 weeks.

OTHER

ABO-GLYC Placebo

3 tablets twice a day, before the main meals (lunch and dinner) continuatively for 24 weeks.

Trial Locations (1)

Unknown

Azienda Ospedaliera Padova, Padua

All Listed Sponsors
collaborator

Latis S.r.l.

INDUSTRY

collaborator

Fondazione Edmund Mach

OTHER

lead

Aboca Spa Societa' Agricola

INDUSTRY

NCT03568409 - ABO-GLYC in Type 2 Diabetes | Biotech Hunter | Biotech Hunter